Physician profile
Atul Chugh
NPI 1447463864
$241,903.18
in general payments reported to CMS, 2019-2025
31 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $35K · 2021: $25K · 2022: $24K · 2023: $11K · 2024: $34K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $29K · Travel and Lodging: $12K · Food and Beverage: $5,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,735.00 |
| Consulting Fee | $29,368.75 |
| Travel and Lodging | $12,002.57 |
| Food and Beverage | $5,606.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $81,537.62 | 2019-2023 | |
| Medtronic, INC. | $77,600.89 | 2021-2025 | Symplicity G3, Resolute Onyx |
| Boston Scientific Corporation | $41,925.72 | 2019-2025 | Watchman Access System, Watchman Flx |
| Angiodynamics, INC. | $20,474.88 | 2019-2025 | Angiovac |
| Biostable Science & Engineering | $9,952.42 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $5,097.02 | 2024 | Tryvio |
| Novartis Pharmaceuticals Corporation | $2,276.27 | 2019-2024 | |
| Edwards Lifesciences Corporation | $1,081.64 | 2019 | |
| Cvrx, INC. | $302.01 | 2023-2024 | Barostim Neo System |
| Heartflow, INC. | $216.05 | 2020-2023 | Ffrct |
| Pfizer INC. | $163.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $162.75 | 2019-2024 | Camzyos |
| Abiomed | $151.50 | 2023 | Impella |
| Janssen Pharmaceuticals, INC | $150.61 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.51 | 2019-2024 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.45 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $125.50 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals Lp | $94.84 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $78.12 | 2023-2025 | Ozempic, Wegovy |
| Abbott Laboratories | $46.49 | 2020-2021 | |
| Philips North America LLC | $37.67 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $33.11 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $30.33 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.97 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $13.84 | 2019 | |
| Shockwave Medical, INC | $13.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2019 | |
| Kestra Medical Technology Services, INC. | $13.16 | 2022 | |
| Elutia, INC. | $12.77 | 2019 | |
| Amgen INC. | $12.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Chugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.